Cargando…

PB2547: ESTIMATING HEALTH-RELATED QUALITY OF LIFE IN ADULT PYRUVATE KINASE DEFICIENCY: A TIME TRADE-OFF UTILITY STUDY

Detalles Bibliográficos
Autores principales:	Higa, Sara, Chua, Gin Nie, Sussex, Anna-Katrine, Lloyd, Andrew, LI, Junlong, Patel, Parija, Morris, Susan, Zagadailov, Erin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429516/ http://dx.doi.org/10.1097/01.HS9.0000976884.17315.b1

Ejemplares similares

PB2359: HEALTHCARE RESOURCE UTILIZATION OF ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A REAL WORLD STUDY USING US VETERANS HEALTH ADMINISTRATION DATA
por: Zagadailov, E., et al.
Publicado: (2022)

P1476: THE CLINICAL CHARACTERISTICS AND OVERALL SURVIVAL OF PATIENTS WITH PYRUVATE KINASE DEFICIENCY IN THE UK: A REAL-WORLD STUDY
por: Higa, Sara, et al.
Publicado: (2023)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

PB1990: GLYCOLYTIC ACTIVITY AND EFFECT OF EX-VIVO TREATMENT WITH THE PYRUVATE KINASE (PK) ACTIVATOR AG-946 IN RED BLOOD CELLS FROM LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS: A PROOF-OF-CONCEPT STUDY
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial
por: Andrae, David A., et al.
Publicado: (2023)

PB2345: ADAPTING PATIENT EDUCATIONAL APPROACHES IN PYRUVATE KINASE DEFICIENCY: EUROPE AND NORTH AMERICA FINDINGS FROM THE AAC PATIENT AND CAREGIVER SURVEY
por: Barcellini, W., et al.
Publicado: (2022)

PB2248: CONCOMITANT HEREDITARY SPHEROCYTOSIS AND PYRUVATE KINASE DEFICIENCY IN A SPANISH FAMILY WITH CHRONIC HEMOLYTIC ANEMIA. CONTRIBUTION OF LASER EKTACYTOMETRY TO CLINICAL DIAGNOSIS
por: Vives Corrons, J.-L., et al.
Publicado: (2022)

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA
por: Smirnova, Svetlana, et al.
Publicado: (2023)

Comment on: Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis: reply
por: Esen, Idil, et al.
Publicado: (2022)

2547: Sinai MedMaker Challenge: A model of experiential team science education
por: Backeris, Peter, et al.
Publicado: (2018)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

PB1794: NATURAL FLAVONOIDS INHIBIT MYELOID NEOPLASM PROLIFERATION BY REGULATING PIM2 KINASE ACTIVITY
por: Wang, Hao, et al.
Publicado: (2023)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
por: Balijepalli, Chakrapani, et al.
Publicado: (2023)

PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX
por: Sonowal, Himangshu, et al.
Publicado: (2023)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
por: Harsløf, Mads, et al.
Publicado: (2023)

2547 Long-term response to treatment and disease recurrence in a prospective cohort of morphea patients
por: Florez-Pollack, Stephanie, et al.
Publicado: (2018)

PB1907: CLINICAL VALUE OF DETECTING ABL KINASE MUTATIONS IN CHRONIC MYELOID LEUKEMIA BASED ON HIGH THROUGHPUT SEQUENCING TECHNOLOGY
por: LING, Z., et al.
Publicado: (2022)

PB1778: PAN-PIM KINASE INHIBITOR PIM447 SHOWS SUPERIOR ANTI-LEUKEMIC EFFECT IN ACUTE ERYTHROID LEUKEMIA
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

PB1978: PATIENT-CENTREDNESS IS PIVOTAL IN A PROSPECTIVE DOSE REDUCTION TRIAL OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
por: Djodikromo, Melissa, et al.
Publicado: (2023)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
por: Bougherira, Soraya
Publicado: (2023)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

Prevalence and Predictors of Vitamin D Inadequacy: A Sample of 2,547 Patients in a Mediterranean Country
por: Salman, Sara, et al.
Publicado: (2021)

PB2120: HIV AND MALIGNANT HEMOPATHIES
por: Khibri, H., et al.
Publicado: (2022)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

PB1985: FACTORS ASSOCIATED WITH TOLERANCE TO PHARMACOLOGICAL THERAPY USING TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS ATTENDED AT FOSCAL IN THE PERIOD 2013-2020.
por: Sossa, Claudia Lucía, et al.
Publicado: (2023)

PB2381: EFFICACY ANALYSIS OF BRUTON’S TYROSINE KINASE INHIBITOR COMBINED REGIMEN IN THE TREATMENT OF ELDERLY PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Shi, Wenyu
Publicado: (2023)

PB2704: PREDICTING HEMATOLOGICAL MALIGNANCIES USING COMPLETE BLOOD CELL COUNTS FROM PRIMARY CARE
por: Christensen, Mathilde, et al.
Publicado: (2023)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

PB2322: TTP AFTER COVID 19
por: Gagloeva, D., et al.
Publicado: (2022)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB2363: REPORTING LANGUAGE IN HAEMATOLOGICAL MALIGNANCIES
por: Watt, S., et al.
Publicado: (2022)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB2601: BLOOD POLLUTION IN THE AGE OF NANO
por: Rolli, Marco
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tqtb3v8cejj583ac2b7342q1ca